Gilead Sciences, Inc. GILD Archived
-0.77%This entry is more than 3 months old and has been archived. Prices reflect the last update.
✅ Key Summary
Gilead Sciences, Inc. focuses on antiviral drugs, particularly for HIV and hepatitis. The company reported solid earnings driven by its key products, but faces challenges from generic competition. The stock is currently trading at $136.30, reflecting a significant premium based on its valuation metrics.
🏢 Company Overview
Gilead Sciences, Inc. is a biopharmaceutical company that develops and commercializes innovative medicines. The company has a strong portfolio of antiviral drugs, particularly for HIV, hepatitis B, hepatitis C, and influenza. Recently, Gilead reported strong earnings, driven primarily by sales of its HIV therapies. However, it is facing increasing competition from generic alternatives, which may impact future revenue growth. The stock's current price of $136.30 indicates a substantial premium, as reflected in its calculated basis point of 85847. Investors should consider the potential for market volatility as Gilead navigates these challenges. Overall, the company maintains a solid position in the industry with ongoing research and development efforts.
📰 Related News
-
Gilead Reports Q1 Earnings BeatPositive earnings surprise boosts investor confidence.
-
Generic Competition Intensifies in Hepatitis C MarketPotential revenue pressure from increased generic offerings.
-
FDA Approves New HIV TreatmentExpansion of product portfolio may enhance market position.
🏭 Competitor Comparison
-
AbbVie Inc. ABBVFocuses on immunology and oncology, providing diversification away from antivirals.
-
Bristol Myers Squibb Company BMYOffers a broad range of therapies, including oncology and cardiovascular drugs.
-
Merck & Co., Inc. MRKCompetes in vaccines and infectious disease treatments, differing from Gilead's antiviral focus.
📅 Gilead Sciences, Inc. discovery history
This stock has been discovered 6 times.
| Discovered | Discovery price | Current price | Return |
|---|---|---|---|
| Sep 17, 2026 | $150.89 | $168.08 | +11.39% |
| Aug 12, 2026 | $135.87 | $170.87 | +25.76% |
| Apr 1, 2026 | $140.30 | $126.34 | -9.95% |
| Jan 30, 2026 | $141.95 | $130.84 | -7.83% |
| Dec 24, 2025 | $125.67 | $138.11 | +9.90% |